PubRank

Andri Rauch

Author PubWeight™ 57.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011 2.98
2 Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clin Infect Dis 2010 2.17
3 Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012 2.04
4 Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009 1.90
5 Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008 1.66
6 Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 2012 1.65
7 Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 2011 1.64
8 Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog 2010 1.63
9 Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 2011 1.61
10 Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection. Blood 2012 1.60
11 Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 2006 1.54
12 Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009 1.54
13 Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010 1.53
14 Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011 1.44
15 Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011 1.30
16 Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008 1.29
17 The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008 1.25
18 Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One 2011 1.24
19 Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One 2010 1.23
20 A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. Elife 2013 1.19
21 Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One 2007 1.16
22 Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreak. Hepatology 2011 1.14
23 Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin. J Acquir Immune Defic Syndr 2005 1.01
24 Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis 2013 0.97
25 HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity. J Allergy Clin Immunol 2013 0.97
26 CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland. J Infect Dis 2009 0.94
27 Parvovirus 4 infection and clinical outcome in high-risk populations. J Infect Dis 2012 0.93
28 A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. J Mass Spectrom 2013 0.92
29 A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011 0.91
30 A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011 0.90
31 Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. J Virol 2013 0.89
32 Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: latent class analysis. AIDS Behav 2012 0.89
33 Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics 2006 0.88
34 Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS One 2011 0.86
35 Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One 2013 0.85
36 Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals. Antivir Ther 2013 0.85
37 Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. J Infect Dis 2014 0.85
38 Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis 2013 0.85
39 Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir. Antimicrob Agents Chemother 2013 0.84
40 Social meets molecular: Combining phylogenetic and latent class analyses to understand HIV-1 transmission in Switzerland. Am J Epidemiol 2014 0.83
41 Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. AIDS 2014 0.82
42 Genetic variations in IL28B and allergic disease in children. PLoS One 2012 0.80
43 Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients. PLoS One 2013 0.78
44 Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia. Clin Infect Dis 2010 0.78
45 Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry. Antivir Ther 2014 0.78
46 Molecular Analyses Define Vα7.2-Jα33+ MAIT Cell Depletion in HIV Infection: A Case-Control Study. Medicine (Baltimore) 2015 0.78
47 Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. AIDS 2011 0.77
48 Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance. Antivir Ther 2009 0.77
49 Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic. J Acquir Immune Defic Syndr 2011 0.76
50 Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient. AIDS 2016 0.75
51 Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection. Antivir Ther 2014 0.75
52 Personalized hepatitis C therapy: opportunities and pitfalls. Expert Rev Mol Diagn 2011 0.75